JAEA
  • help
  • PC | SP
  • JP | EN
          
Refine your search：     
Report No.
 - 
Clear All
Search Results: Records 1-6 displayed on this page of 6
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

Journal Articles

Development of a Rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals

Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Ono, Masahiro*; Hanaoka, Hirofumi*; Ishino, Seigo*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*

Bioconjugate Chemistry, 16(4), p.751 - 757, 2005/07

https://doi.org/10.1021/bc040249w
 Times Cited Count：62 Percentile：87.15(Biochemical Research Methods)

Rhenium-186-1-hydroxyethylidene-1,1-diphosphonate ($$^{186}$$Re-HEDP) has been used for the palliation of metastatic bone pain. Delayed blood clearance and high gastric uptake of radioactivity have been observed upon injection, due to the instability of $$^{186}$$Re-HEDP in vivo. In this study, on the basis of the concept of bifunctional radiopharmaceuticals, we designed a stable $$^{186}$$Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate ($$^{186}$$Re-MAG3-HBP). After purification by HPLC, $$^{186}$$Re-MAG3-HBP was synthesized with a radiochemical purity of over 95%. In biodistribution experiments, the radioactivity level of$$^{186}$$Re-MAG3-HBP in bone was significantly higher than that of $$^{186}$$Re-HEDP. Blood clearance of $$^{186}$$Re-MAG3-HBP was faster than that of $$^{186}$$Re-HEDP. In addition, the gastric accumulation of $$^{186}$$Re-MAG3-HBP radioactivity was lower than that of $$^{186}$$Re-HEDP. In conclusion, $$^{186}$$Re-MAG3-HBP is expected to be a useful radiopharmaceutical for the palliation of metastatic bone pain.

Journal Articles

Design of a radiopharmaceutical for the palliation of painful bone metastases; Rhenium-186-labeled bisphosphonate derivative

Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*

Journal of Labelled Compounds and Radiopharmaceuticals, 47(11), p.753 - 761, 2004/11

https://doi.org/10.1002/jlcr.864
 Times Cited Count：29 Percentile：62.74(Biochemical Research Methods)

no abstracts in English

Journal Articles

Analysis of $$^{188}$$Re-EDTMP complexes by HPLC and ultrafiltration

Hashimoto, Kazuyuki; Matsuoka, Hiromitsu

Radiochimica Acta, 92(4-6), p.285 - 290, 2004/07

https://doi.org/10.1524/ract.92.4.285.35587
 Times Cited Count：1 Percentile：9.92(Chemistry, Inorganic & Nuclear)

no abstracts in English

Journal Articles

Separation, purification of $$^{177}$$Lu$$^{m}$$ and preparation of $$^{177}$$Lu$$^{m}$$-EDTMP

Chen, D.*; Hashimoto, Kazuyuki

Journal of Nuclear and Radiochemistry, 26(2), p.84 - 87, 2004/05

no abstracts in English

Journal Articles

Skeletal affinity of Tc(V)-DMS is bone cell mediated and pH dependent

Horiuchi, Kazuko*; Konno, Aya*; Ueda, Mayumi*; Fukuda, Yoko*; Nishio, Saori*; Hashimoto, Kazuyuki; Saji, Hideo*

European Journal of Nuclear Medicine and Molecular Imaging, 31(3), p.388 - 398, 2004/03

https://doi.org/10.1007/s00259-003-1364-1
 Times Cited Count：21 Percentile：50.12(Radiology, Nuclear Medicine & Medical Imaging)

no abstracts in English

Journal Articles

Labeling with radioactive rhenium for the purpose of the pain relief of cancerous bone metastasis

Ogawa, Kazuma*; Ono, Masahiro*; Fujioka, Yasushi*; Saji, Hideo*; Mukai, Takahiro*; Konishi, Junji*; Uehara, Tomoya*; Arano, Yasushi*; Onoma, Katsuyuki

Kaku Igaku, 37(5), P. 577, 2000/09

no abstracts in English

6 (Records 1-6 displayed on this page)
  • 1